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Abstract
Purpose:  Pupillary  dilatation  with  three  types  of  eye  drops  is  used  regularly  in  the  clinic;  how-
ever, a  mixture  of  these  drops  in  a  single  bottle  may  be  more  beneﬁcial  in  reducing  workloads
and resources.  This  study  compared  the  efﬁcacy  in  pupillary  dilatation  between  two  protocols
of dilating  drop  instillation.
Methods:  This  prospective,  randomized,  comparative  study  included  30  eligible  Thai  patients.
The patients  randomly  received  preoperative  pupillary  dilatations  by  either  the  conventional
protocol (1%  tropicamide  (T),  10%  phenylephrine  (P)  and  0.1%  diclofenac  (D)  in  three  separate
bottles)  or  the  ﬁxed  combination  (TPD)  protocol  which  had  the  three  types  of  eye  drops  mixed
in a  single  bottle  in  a  ratio  of  4:3:3.  The  chi-square  test  and  independent  t-test  were  used  to
analyze  the  data.
Results:  The  conventional  protocol  group  and  TPD  protocol  group  each  had  15  patients.  Sixty
minutes after  the  initial  instillation,  all  patients  in  the  TPD  protocol  and  13  patients  (86.7%)  in
conventional  protocol  achieved  at  least  6  mm  in  the  shortest  diameter.  The  mydriatic  rate
between protocols  showed  no  difference.  In  patients  who  received  the  TPD  protocol,  the
systemic effects  on  the  mean  arterial  blood  pressure  and  pulse  rate  decreased  over  time.
Conclusion:  The  mixture  of  tropicamide,  phenylephrine  and  diclofenac  had  a  comparable  efﬁ-
cacy for  a  pupillary  dilatation  to  the  conventional  dilating  drops  in  separate  bottles.  The
systemic complications  on  blood  pressure  and  arterial  pulse  of  the  TPD  mixture  were  less  than
the conventional  protocol.
Trial  registration:  TCTR20130325001.
© 2016  Spanish  General  Council  of  Optometry.  Published  by  Elsevier  Espan˜a,  S.L.U.  This  is  an
open access  article  under  the  CC  BY-NC-ND  license  (http://creativecommons.org/licenses/by-
nc-nd/4.0/).Please  cite  this  article  in  press  as:  Bhurayanontachai  P,  et  al.  Efﬁcacy  of  an  eye  drop  mixture  for  pupillary  dilatation:  A
randomized  comparative  study.  J  Optom.  (2016),  http://dx.doi.org/10.1016/j.optom.2016.04.007
∗ Corresponding author at: Department of Ophthalmology, Faculty of medicine, Prince of Songkla University, Hat Yai, Songkhla 90110,
Thailand.
E-mail addresses: patama103@yahoo.com.au, patamabhu@gmail.com (P. Bhurayanontachai).
http://dx.doi.org/10.1016/j.optom.2016.04.007
1888-4296/© 2016 Spanish General Council of Optometry. Published by Elsevier Espan˜a, S.L.U. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
ARTICLE IN PRESS+ModelOPTOM-194; No. of Pages 6
2  P.  Bhurayanontachai  et  al.
PALABRAS  CLAVE
Diclofenaco;
Midriático;
Fenilefrina;
Dilatación  de  la
pupila;
Tropicamida
Eﬁcacia  de  la  mezcla  de  gotas  oculares  para  la  dilatación  de  la  pupila:  estudio
aleatorizado  y  comparativo
Resumen
Objetivo:  La  dilatación  de  la  pupila  con  tres  tipos  de  gotas  oculares  se  utiliza  normalmente  en
la práctica  clínica;  sin  embargo,  la  mezcla  de  dichas  gotas  en  un  único  envase  puede  resultar
más beneﬁciosa  a  la  hora  de  reducir  las  cargas  de  trabajo  y  los  recursos.  Este  estudio  comparó
la eﬁcacia  entre  dos  protocolos  de  dilatación  de  pupilas.
Métodos:  Este  estudio  prospectivo,  aleatorizado  y  comparativo  incluyó  a  30  pacientes  tai-
landeses elegibles.  A  dichos  pacientes  se  les  dilató  aleatoria  y  preoperatoriamente  la  pupila
utilizando  el  protocolo  convencional  (1%  tropicamida  (T),  10%  fenilefrina  (P)  y  0,1%  diclofenaco
(D) en  tres  envases  separados),  o  el  protocolo  de  combinación  ﬁja  (TPD),  que  contenía  los  tres
tipos de  gotas  oculares  mezclados  en  un  único  envase,  a  un  ratio  de  4:3:3.  Se  utilizaron  las
pruebas de  2 y  la  prueba  independiente  t  para  analizar  los  datos.
Resultados:  Tanto  el  grupo  de  protocolo  convencional  como  el  grupo  TPD  incluyeron  a  15
pacientes.  A  los  sesenta  minutos  de  la  instilación  inicial,  todos  los  pacientes  del  protocolo  TPD
y 13  pacientes  (86,7%)  del  protocolo  convencional  lograron  un  mínimo  de  6  mm  en  el  diámetro
menor. La  tasa  midriática  entre  ambos  protocolos  no  reﬂejó  diferencia  alguna.  En  los  pacientes
del protocolo  TPD,  los  efectos  sistémicos  sobre  la  presión  sanguínea  media  y  el  índice  de  pulso
disminuyeron  con  el  tiempo.
Conclusión:  La  mezcla  de  tropicamida,  fenilefrina  y  diclofenaco  mostró  una  eﬁcacia  compa-
rable a  la  de  las  gotas  para  dilatación  de  pupilas  suministradas  en  envases  separados.  Las
complicaciones  sistémicas  sobre  la  presión  sanguínea  y  la  presión  arterial  de  la  mezcla  de  TPD
fueron menores  a  las  del  protocolo  convencional.
Registro  del  ensayo: TCTR20130325001.
© 2016  Spanish  General  Council  of  Optometry.  Publicado  por  Elsevier  Espan˜a,  S.L.U.  Este  es  un
art´ıculo Open  Access  bajo  la  CC  BY-NC-ND  licencia  (http://creativecommons.org/licencias/by-
nc-nd/4.0/).
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Exclusion  criteriantroduction
upillary  dilatation  is  necessary  for  a  fundus  examina-
ion  and  ophthalmic  procedures.  The  mydriatic  agents
hat  are  generally  available  in  the  eye  clinic  are  tropi-
amide  and  phenylephrine.  For  an  intraocular  examination
r  operation,  a  non-steroidal  anti-inﬂammatory  drug  is
dditionally  required  to  prolong  the  mydriatic  effect  and
essen  post-operative  inﬂammation.1,2 The  conventional  for-
ula  of  pre-operative  pupillary  dilatation  commonly  used
n  the  hospital  is  1%  tropicamide,  10%  phenylephrine,  and
.1%  diclofenac  in  separate  bottles.  Each  eye-drop  bottle
ontains  preservatives  to  inhibit  microbial  contamination.
owever,  these  preservatives  have  been  linked  to  unwanted
cular  surface  side  effects,  such  as  stinging,  redness  and
orneal  punctate  epithelial  erosion.  A  combination  of  pre-
perative  eye  drops  in  one  bottle  may  not  only  reduce  the
requency  of  multiple  eye  drop  administrations  but  may
lso  reduce  the  ocular  and  systemic  complications.3--5 There
ere  some  reports  on  the  efﬁcacy  and  safety  of  a  combi-
ation  of  tropicamide  and  phenylephrine,4--6 but  there  is  no
eport  on  a  combination  of  tropicamide,  phenylephrine  and
iclofenac.Please  cite  this  article  in  press  as:  Bhurayanontachai  P,  et  al.  
randomized  comparative  study.  J  Optom.  (2016),  http://dx.do
The  objective  of  this  study  is  to  compare  the  mydriatic
fﬁcacy  of  a  mixture  of  tropicamide,  phenylephrine  and
iclofenac  in  a  single  eye-drop  bottle  to  the  conventional
P
practice  of  applying  the  eye  drops  from  separate
ottles.
ethods
nclusion  criteria
his  randomized  prospective  study  was  performed  in  accor-
ance  with  the  declaration  of  Helsinki  and  was  approved
y  the  Ethics  Committee  of  the  Faculty  of  Medicine,  Prince
f  Songkla  University,  Thailand  (EC  56-153-02-1-2).  We
ollowed  our  institution  protocols  regarding  patient  data
rotection.  Written  informed  consents  were  obtained  from
0  consecutive,  eligible  patients  before  the  study  began.
he  inclusion  criteria  were  patients  of  18  years  old  or  older
nd  scheduled  for  an  operation  at  Songklanagarind  Hospi-
al,  Prince  of  Songkla  University,  Thailand  from  April  to  July
013.  The  pre-operative  fasting  plasma  glucose  of  all  dia-
etic  patients  was  less  than  200  mg/dl.  The  resting  systolic
ressure  was  ≤160  mmHg  and  the  resting  diastolic  pressure
as  ≤90  mmHg.Efﬁcacy  of  an  eye  drop  mixture  for  pupillary  dilatation:  A
i.org/10.1016/j.optom.2016.04.007
atients  with  a  risk  of  angle-closure,  uncontrolled  blood
ressure,  pregnancy,  iris  or  pupil  abnormality,  or  a  history
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of  allergic  reactions  to  any  of  the  investigating  drugs  were
excluded  from  the  study.
Sample  size  of  patients
The  sample  size  of  30  patients  was  calculated  from
the  formula  n  >  2  ×  (Z˛/2 ×  /d1)2,  where  Z˛ =  1.96,  
(sigma)  =  0.6,  d1 (delta)  =  8.0--7.0  mm  (mean  =  8.0  mm,  lower
limit  =  7.0  mm).  The  calculated  number  of  recruited  patients
was  at  least  14  for  each  group  with  an  anticipated  20%  drop-
out  allowance.
Dilating  eye  drops
The  eye  drops  for  the  conventional  protocol  included  three
commercial  preparations:  1%  tropicamide  (Mydriacyl®,
Alcon-Couvreur,  Puurs,  Belgium),  10%  phenylephrine
(Phenylephrine  HCL®,  Silom  Medical  Co.,  Ltd,  Thailand)
and  0.1%  diclofenac  (Voltaren  Ophtha  Oftalmico®,  Novartis
PharmaAG,  Basel,  Switzerland)  in  separate  bottles.  The
mixture  of  the  ﬁxed  combination  protocol  was  a  combina-
tion  of  those  commercial  preparations  in  a  ratio  of  4:3:3
that  resulted  in  a  ﬁnal  concentration  of  0.4%  tropicamide
(T),  3%  phenylephrine  (P)  and  0.03%  diclofenac  (D).  This
reduced  concentration  mixture  (TPD)  was  labeled  for
the  TPD  protocol.  A  pharmacist  (PA)  of  the  hospital  was
responsible  for  the  preparation  of  this  TPD  mixture.  The
mixture  was  prepared  from  commercially  available  eye
drops  instead  of  using  the  primary  preservative-free  phar-
maceutical  products.  This  mixture  was  easily  prepared  in
the  ofﬁce  and  dispensed  to  several  units.  The  precipitation
of  tropicamide,  which  may  occur  when  mixed  with  phenyle-
phrine,  was  less  likely  to  occur  at  a  concentration  less  than
0.5%.6 The  ﬁxed  combination  of  these  three  medications
was  chemically  stable.
Study  protocols
Eligible  patients  were  randomized  into  two  groups  and
received  either  a  conventional  or  TPD  formula  for  pupillary
dilatation.  Patients  in  the  conventional  protocol  received
eye  drops  every  5  min  (Table  1).  Patients  in  the  TPD  pro-
tocol  received  the  TPD  mixture  every  15  min.  Other  eye
drops,  such  as  topical  anesthetics,  were  not  allowed  before
the  study.  The  measurements  of  pupillary  diameters,  pulse
and  blood  pressure  were  taken  at  baseline,  10  min,  25  min
and  60  min  after  the  ﬁrst  eye  drop  instillation  of  each  pro-
tocol  that  was  administered.  The  pupillary  diameter  was
measured  in  both  horizontal  and  vertical  dimensions  by  an
infrared  pupillometer  (Colvard®,  OASIS  Medical  Inc.,  CA,
USA)  and  was  read  by  only  one  investigator  (SS).  The  average
of  these  two  values  was  recorded  for  the  analysis.  The  sitting
arterial  blood  pressure  and  pulse  were  measured  by  an  auto-
matic  sphygmomanometer  (Spirit®,  Spirit  Medical  Co.,  Ltd.,
Taiwan,  ROC).  The  target  pupillary  size  was  at  least  6  mm  inPlease  cite  this  article  in  press  as:  Bhurayanontachai  P,  et  al.  Efﬁcacy  of  an  eye  drop  mixture  for  pupillary  dilatation:  A
randomized  comparative  study.  J  Optom.  (2016),  http://dx.doi.org/10.1016/j.optom.2016.04.007
the  shortest  dimension  within  60  min.  With  a  pupillary  size
of  at  least  6  mm  in  diameter,  the  fundus  examination  along
with  most  intraocular  operations  achieved  a  sufﬁcient  view
of  the  lens,  retina  and  vitreous.
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Table  2  Baseline  demographic  data.
Characteristics  Conventional  (n  =  15)  TPD  (n  =  15)  p  value
Gender,  n  (%)
Male  7  (46.7)  9  (60.0)  0.714
Female 8  (53.3) 6  (40.0)
Age (years,  mean  ±  SD) 61.53  ±  16.95 64.27  ±  11.77 0.612
Underlying  diseases,  n  (%)
Absence  6  (40.0)  9  (60.0)  0.465
Presence 9  (60.0)  6  (40.0)
Studied eye,  n  (%)
Right  8  (53.3)  8  (53.3)  1.000
Left 7  (46.7)  7  (46.7)
Lens status,  n  (%)
Phakic  14  (93.3)  13  (86.7)  0.595
Pseudophakic  0  (0)  1  (6.7)
Aphakic 1  (6.7)  1  (6.7)
Previous  ocular  operation,  n  (%)
Never  8  (53.3)  6  (40.0)  0.714
Presence 7  (46.7)  9  (60.0)
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pThe  primary  outcome  was  a  difference  of  the  mean
upillary  diameters  at  60  min  between  the  two  protocols.
he  secondary  outcomes  were  changes  in  the  mean  arte-
ial  blood  pressure  (MAP)  and  arterial  pulse.  A  formula
or  the  MAP  calculation  was  [(2  ×  diastolic  value)  +  systolic
alue]/3.
tatistical  analysis
 comparative  analysis  of  continuous  data  was  performed  by
n  independent  t-test.  A  comparative  analysis  of  categorical
ata  was  performed  by  a  Chi-square  test.  SPSS  version  16.0
as  used  for  these  analyses.  A  p-value  of  0.05  or  less  was
onsidered  statistically  signiﬁcant.
esults
atient  demographic  data
hirty  patients  (16  male,  14  female)  were  enrolled  in  the
tudy  and  were  randomized  to  receive  the  conventional  or
he  TPD  protocol.  The  patients’  ages  ranged  from  23  to  83
ears.  Underlying  diseases  such  as  diabetes  mellitus  (DM),
ypertension  (HT)  and  dyslipidemia  were  reported  in  60%  of
atients  in  the  conventional  group  and  in  40%  of  patients
n  the  TPD  group.  Three  patients  (20%)  in  each  group  had
iabetes  mellitus.  Eight  patients  (53.3%)  in  the  conventional
roup  and  5  patients  (33.3%)  in  the  TPD  group  had  hyperten-
ion.  Two  patients  (13.3%)  in  each  group  had  dyslipidemia.
owever,  none  of  these  underlying  diseases  were  statis-
ically  different  between  the  groups  (p  =  0.465  for  overallPlease  cite  this  article  in  press  as:  Bhurayanontachai  P,  et  al.  
randomized  comparative  study.  J  Optom.  (2016),  http://dx.do
onditions,  p  =  1.00  for  DM,  p  =  0.46  for  HT,  and  p  =  1.00  for
yslipidemia).  Other  baseline  characteristics  of  the  patients
re  shown  in  Table  2.  There  were  no  differences  in  the  basic
haracteristics  of  the  patients  between  the  protocols.
o
b
c
(rimary  outcome
t  baseline,  the  mean  pupillary  size  of  the  patients  in
he  TPD  group  was  slightly  larger  than  the  conventional
roup.  However,  the  average  difference  in  the  ﬁnal  pupil-
ary  size  from  baseline  in  both  groups  was  equal.  The
upil  diameter  increased  by  4.12  ±  1.06  mm  in  the  TPD
roup  and  by  4.10  ±  0.80  mm  in  the  conventional  group
Table  3).  The  average  rate  of  mydriasis  in  the  TPD  group
as  0.0687  mm/min  and  0.0683  mm/min  in  the  conven-
ional  group.  There  was  no  statistical  difference  of  mydriatic
ates  between  the  two  protocols  (Fig.  1).  All  patients
n  the  TPD  group  and  13  patients  (86.7%)  in  the  con-
entional  group  achieved  their  target  pupillary  size  at
0  min.  Changes  in  the  pupil  diameter  from  baseline  were
ot  signiﬁcantly  different  between  protocols  (Table  3).
hese  changes  also  showed  no  differences  between  nor-
al  patients  and  patients  with  underlying  diseases  at  every
ime  point  in  the  subgroup  analyses  of  both  protocols
Table  4).
econdary  outcome
he  changes  in  MAP  of  the  patients  at  each  time  point
fter  initiating  the  dilating  drops  were  not  signiﬁcantly
ifferent  between  the  protocols.  However,  the  changes
f  arterial  pulse  from  the  baseline  were  strikingly  differ-
nt  between  the  two  protocols.  While  the  mean  arterial
ulse  of  the  patients  who  received  the  conventional  pro-
ocol  increased  over  time,  the  mean  arterial  pulse  of  the
atients  who  were  administered  the  TPD  protocol  decreasedEfﬁcacy  of  an  eye  drop  mixture  for  pupillary  dilatation:  A
i.org/10.1016/j.optom.2016.04.007
ver  time  (p  <  0.005).  Although  the  change  in  the  MAP  from
aseline  was  not  signiﬁcantly  different  between  the  proto-
ols,  the  values  showed  a  tendency  to  decrease  over  time
Table  3).
Please  cite  this  article  in  press  as:  Bhurayanontachai  P,  et  al.  
randomized  comparative  study.  J  Optom.  (2016),  http://dx.do
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Table  3  Pupillary  diameter,  pulse  and  mean  arterial  blood  pressure  changes  over  time.
Variable  Conventional  (n  =  15)  TPD  (n  =  15)  p  value
Pupil  diameter  (mm,  mean  ±  SD)
Baseline  3.45  ±  0.89  4.33  ±  0.82  0.009*
At  10  min 4.95  ±  1.41 6.02  ±  1.05 0.026*
(+1.50  ±  0.95) (+1.68  ±  0.98) (0.607)
At 25  min  6.33  ±  1.44  7.50  ±  0.93  0.013*
(+2.88  ±  0.95)  (+3.17  ±  0.97)  (0.427)
At 60  min  7.55  ±  1.25  8.45  ±  0.77  0.025*
(+4.10  ±  0.80)  (+4.12  ±  1.06)  (0.961)
Pulse (per  min,  mean  ±  SD)
Baseline  65.87  ±  13.56  66.60  ±  11.54  0.876
At 10  min  67.07  ±  13.38  63.80  ±  10.37  0.461
(+1.20 ±  3.49)  (−2.80  ±  3.26)  (0.003*)
At 25  min  67.93  ±  13.46  63.00  ±  10.64  0.275
(+2.07 ±  4.38)  (−3.60  ±  4.10)  (0.001*)
At 60  min  67.87  ±  12.32  61.67  ±  9.84  0.139
(+2.00 ±  7.19) (−4.93  ±  4.43)  (0.004*)
MAP (mmHg,  mean  ±  SD)
Baseline  88.91  ±  8.26  91.62  ±  8.00  0.369
At 10  min  85.37  ±  13.63  88.98  ±  8.21  0.388
(−3.54 ±  12.01)  (−2.64  ±  5.91)  (0.798)
At 25  min  89.60  ±  7.55  90.24  ±  8.32  0.826
(+0.69 ±  5.15)  (−1.38  ±  5.031)  (0.288)
At 60  min  91.84  ±  8.23  89.33  ±  10.86  0.481
(+2.93 ±  7.84)  (−2.29  ±  10.68)  (0.138)
MAP, mean arterial pressure.
The mean changes from baseline are shown in italics and parentheses.
* statistical signiﬁcance.
Discussion
Our  study  included  DM  and  HT  patients:  60%  in  the  conven-
tional  group  and  40%  in  the  TPD  group.  Although  Table  2
demonstrates  that  patients  with  these  underlying  diseases
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Figure  1  Pupillary  diameter  at  each  time  point.
w
h
(
t
w
r
c
t
e
o
t
w
b
t
(
p
r
t
t
p
l
m
c
e
t
f
bere  not  statistically  different,  the  underlying  diseases  did
ave  a  more  or  less  effect  on  the  pupil  size  at  baseline
Table  3).  The  mean  baseline  pupil  size  of  the  patients  in
he  conventional  group  was  smaller  than  the  TPD  group
ith  a  signiﬁcant  difference.  Therefore,  concerning  the
ates  of  pupillary  dilatation,  it  would  be  more  useful  to
ompare  the  effect  of  the  eye  drops  between  protocols
han  the  sizes  of  the  ﬁnal  pupillary  diameter.  At  the
nd  of  the  study,  both  protocols  yielded  an  equal  degree
f  pupillary  dilatation  and  the  rate  of  pupillary  dilata-
ion  was  not  different  between  the  two  groups.  There
as  also  no  statistical  difference  in  the  pupillary  sizes
etween  the  patients  with  DM  or  HT  who  received  either
he  conventional  or  TPD  protocol  at  every  time  point
Table  4).
A mixture  of  reduced  concentration  of  tropicamide  and
henylephrine  in  patients  with  darkly  pigmented  irides  was
eported  to  be  sufﬁciently  effective  for  pupillary  dilata-
ion  in  indirect  ophthalmoscopy.4,5 This  study  also  showed
hat  the  lower  concentration  of  dilating  drops  in  the  TPD
rotocol  neither  compromised  the  average  gain  in  pupil-
ary  increment  nor  the  mean  mydriatic  rate  at  the  60  min
ark.  Diclofenac  can  be  added  into  the  mixture  of  tropi-
amide  and  phenylephrine  without  disturbing  the  mydriaticEfﬁcacy  of  an  eye  drop  mixture  for  pupillary  dilatation:  A
i.org/10.1016/j.optom.2016.04.007
ffects.  However,  the  prolonged  efﬁcacy  of  pupillary  dilata-
ion  during  the  intraoperative  period  may  be  required  in  a
uture  study.  The  limitation  of  this  study  was  the  small  num-
er  of  subjects.  Therefore,  a  subgroup  analysis  of  mydriatic
ARTICLE IN PRESS+ModelOPTOM-194; No. of Pages 6
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Table  4  Pupillary  diameter  changes  compared  between  normal  patients  and  patients  with  underlying  diabetes  mellitus  or
hypertension.
Variable  Conventional  p  value  TPD  p  value
Normal  patients  Patients  with
DM  or  HT
Normal  patients  Patients  with
DM  or  HT
Pupil  diameter  (mm,  mean  ±  SD)
Baseline  3.42  ±  1.11  3.53  ±  0.81  0.827  4.42  ±  1.03  4.25  ±  0.43  0.739
At 10  min  4.92  ±  1.63  4.84  ±  1.39  0.929  6.08  ±  1.05  6.10  ±  1.18  0.979
At 25  min  5.88  ±  1.69  6.59  ±  1.34  0.390  7.61  ±  0.93  7.40  ±  1.10  0.708
At 60  min  7.21  ±  1.76  7.81  ±  0.85  0.465  8.58  ±  0.72  8.30  ±  0.97  0.544
Pupil diameter  difference  from  baseline  (mm,  mean  ±  SD)
At 10  min  -- baseline 1.50  ±  0.63 1.31  ±  1.08 0.712 1.67  ±  0.86  1.85  ±  1.32  0.756
At 25  min  --  baseline  2.45  ±  0.68  3.06  ±  1.06  0.247  3.19  ±  0.90  3.15  ±  1.29  0.941
At 60  min  --  baseline  3.79  ±  0.68  4.28  ±  0.89  0.284  4.17  ±  1.13  4.05  ±  1.15  0.857
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RDM, diabetes mellitus; HT, hypertension.
esponse  between  patients  with  underlying  diseases  and  nor-
al  patients  could  not  be  provided.
In  regards  to  the  systemic  effects  on  the  MAP  and  pulse,
henylephrine  has  a  sympathetic  stimulation  on  the  heart
ate  and,  therefore,  probably  induces  a  raise  of  the  arterial
lood  pressure  and  pulse.  Each  patient  in  the  conventional
rotocol  received  3  drops  of  10%  phenylephrine  while  each
atient  in  the  TPD  protocol  received  4  drops  of  3%  phenyle-
hrine.  Therefore,  the  total  amount  of  phenylephrine  in  the
onventional  group  of  patients  was  much  higher  than  the
atients  in  the  TPD  group.  This  may  be  the  reason  the  TPD
rotocol  had  fewer  patients  with  cardiovascular  side  effects
han  patients  who  received  the  conventional  protocol.  The
endency  of  the  mean  arterial  pulse  to  decrease  over  time
n  the  TPD  group  may  occur  from  a  full  rest  of  the  patient
ith  less  sympathetic  stimulation  from  the  eye  drops.  A  sim-
lar  result  was  also  reported  in  a  previous  study.5 Therefore,
he  TPD  protocol  may  be  more  beneﬁcial  in  patients  with
ystemic  hypertension  or  cardiovascular  diseases.
Patients  in  the  conventional  protocol  received  the  eye
rops  10  times  while  patients  in  the  TPD  protocol  received
he  mixture  only  4  times.  As  a  result,  if  the  TPD  protocol
an  yield  an  equal  dilating  efﬁcacy  compared  to  the  conven-
ional  protocol  while  requiring  less  work,  the  TPD  protocol
s  preferred  in  daily  practice.
onclusions
he  TPD  protocol  with  the  ﬁxed  combination  of  tropicamide,
henylephrine  and  diclofenac  is  equally  effective  as  the  con-
entional  protocol  for  preoperative  pupillary  dilatation  with
educed  side  effects  in  the  patient’s  blood  pressure.Please  cite  this  article  in  press  as:  Bhurayanontachai  P,  et  al.  
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